SSTR antagonist-based PRRT may outperform traditional agonist-based therapy for neuroendocrine tumors | Research

The takeaway

Somatostatin receptor antagonist [177Lu]Lu-satoreotide tetraxetan binds more receptor sites and shows prolonged tumor retention compared to traditional agonists, offering potentially superior PRRT for neuroendocrine tumors.

More binding, longer retention
SSTR antagonists bind more tumor receptor sites and stay attached longer than traditional agonists used in current PRRT

What the researchers found

SSTR antagonists bind more receptor sites and show prolonged tumor retention compared to agonists despite minimal internalization. [177Lu]Lu-satoreotide tetraxetan is the most extensively studied antagonist with accumulating preclinical and clinical evidence of efficacy and safety.

Why it matters

If SSTR antagonists deliver more radiation to tumors than agonists, they could significantly improve PRRT outcomes for neuroendocrine tumor patients—a meaningful advance for a therapy already considered transformative.

How the study worked

Narrative review of preclinical and clinical data on [177Lu]Lu-satoreotide tetraxetan and other SSTR antagonists for PRRT in neuroendocrine tumors.

What this study cannot tell us

Many findings are preclinical or early clinical. Head-to-head comparisons with agonist-based PRRT are limited. Long-term safety of SSTR antagonist PRRT not fully characterized.

How to read the evidence

Narrative review of accumulating preclinical and early clinical evidence. Phase 3 trial data still needed for definitive comparison with agonist PRRT.

When this study was published

Published in 2025; reviews the most studied SSTR antagonist for next-generation PRRT.

The bigger picture

This challenges the fundamental assumption that receptor internalization is necessary for effective PRRT. If validated in phase 3 trials, antagonist-based PRRT could become the new standard, potentially improving outcomes for thousands of NET patients.

Questions still open

Will randomized phase 3 trials confirm antagonist superiority over agonist PRRT?
Does greater receptor binding translate to better clinical outcomes?
What is the optimal patient selection for antagonist vs agonist PRRT?

Common questions

What is the difference between agonist and antagonist PRRT?

Current PRRT uses agonist peptides that activate somatostatin receptors and get pulled inside tumor cells, delivering radiation internally. Antagonist peptides block the receptor without entering the cell but bind to more receptor sites and stay attached longer, potentially delivering more total radiation to the tumor surface.

Could antagonist PRRT work better?

Early evidence suggests yes—antagonists like satoreotide tetraxetan bind more receptor sites and have longer tumor retention. However, large clinical trials comparing antagonist and agonist PRRT head-to-head are still needed to confirm whether this translates to better patient outcomes.

Read the original research

The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors.

Seminars in nuclear medicine

View on PubMed ↗Publisher’s paper ↗

Citation

Shekhda, Kalyan Mansukhbhai; Navalkissoor, Shaunak. (2025). The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors.. Seminars in nuclear medicine. https://doi.org/10.1053/j.semnuclmed.2025.07.002